ClinicalTrials.gg
CompletedNCT04882007CoTikiSUpdated Jun 23, 2026Results posted

Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis

A Phase 2 interventional study of OSE-127 and Placebo in Ulcerative Colitis, sponsored by OSE Immunotherapeutics. Completed at 55 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by OSE Immunotherapeutics · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Oct 2020, registered Apr 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 90 studies in Colitis, Ulcerative with a site in Bulgaria — 9 open to participants now, 24 under way, 16 of them phase 3. Colitis, Ulcerative · Bulgaria.

Enrollment
68th of 89
136 · median 280
Started
2020
with 4 others
Phase 2
41 of 90
1 open now
Registered
56th of 90
by date

Among the 90 studies in Colitis, Ulcerative with a site in Bulgaria, this one is the 68th largest by enrollment of the 89 interventional ones that give a count, is one of 5 that started in 2020, is one of 41 in phase 2, and was the 56th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

9 of the 90 studies in Colitis, Ulcerative with a site in Bulgaria are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Bulgaria have not opened yet or have stopped. Only those recruiting at a site in Bulgaria →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Colitis, Ulcerative with a site in Bulgaria, or all of them as a file.
02

Study summary

This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate to severe active ulcerative colitis.

03

Conditions studied

  • Ulcerative Colitis

Keywords

  • ulcerative colitis
  • inflammatory bowel diseases
  • Auto-Immune Diseases
  • CD127/IL-7Rα Antagonist
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated document indicating that the patient has been informed of all the pertinent aspects of the trial prior to enrollment
  2. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
  3. Willingness to refrain from live or attenuated vaccines during the study and for 12 weeks after last dose
  4. Male or female 18 to 75 years of age, inclusive
  5. Diagnosis of moderate to severe active UC made at least 3 months before the screening visit. The diagnosis of UC must have been confirmed by endoscopy, with a minimal extent of 15 cm from anal margin and histology (Moderate to severe active UC is defined by a modified Mayo score between 4 and 9, inclusive. The modified Mayo score is defined by the addition of the rectal bleeding subscore, the stool frequency sub-score, and the endoscopic sub-score. Thus, to be included, a patient must have the following:

    1. a rectal bleeding score ≥ 1,
    2. a stool frequency score ≥ 1 (sub-score calculated before bowel preparation), and
    3. an endoscopic sub-score ≥ 2
  6. No previous biologic therapy (i.e., TNF antagonists, vedolizumab or ustekinumab) and prior or current UC documented medication history that includes at least 1 of the following:

    1. agents

OR

Previous or current biologic therapy

Exclusion criteria

Exclusion Criteria:

  1. Stoma, proctocolectomy, or subtotal colectomy
  2. Physician judgment that patient is likely to require any surgery for UC during the study duration, or double-blind phase duration at least
  3. Evidence of fulminant colitis, toxic megacolon, or perforation
  4. Current or recent (within 4 weeks prior to screening) hospitalization for UC care and/or treatment with IV
  5. The following laboratory results at screening:

    1. Elevation at screening of aminotransferase (), alanine aminotransferase (ALT) > 3 × the (ULN) or total > 2 × ULN (unless due to Gilbert's disease) or evidence of chronic liver disease
    2. count \< 100,000/mm3
    3. (Hgb) \< 8.5 g/dL
    4. Neutrophils \< 1500/mm3
    5. Lymphocytes \< 800/mm3
    6. Absolute white blood cell (WBC) count \< 3000/mm3
  6. Crohn's disease or indeterminate colitis or any other diagnosis not consisting with UC
  7. History or evidence of incompletely resected colonic dysplasia or unconventional lesion at risk of colonic adenocarcinoma
  8. Stool culture or other examination positive for enteric pathogen, including Clostridium difficile (C. diff) toxin. If positive, the patient should be treated and rescreening is allowed.
  9. Men or women with not willing to use adequate during the study. Adequate birth control includes surgical sterilization, intrauterine device, oral contraceptive, contraceptive patch, long-acting injectable contraceptive, partner's vasectomy, double-barrier method (condom, diaphragm with spermicide), or abstinence during study and 30 days following the last follow-up visit. Women of childbearing potential will enter the study after a negative pregnancy test.
  10. Breastfeeding
  11. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) from screening through the end of the study
  12. Use of topical steroids and/or topical 5-aminosalicylic acid preparations within 2 weeks before the screening visit (all such medications should be withdrawn at least 2 weeks prior to the screening visit)
  13. Use of antidiarrheals within 2 weeks before the screening visit (all such medications should be withdrawn at least 2 weeks prior to the screening visit)
  14. Treatment with azathioprine, 6-MP, methotrexate (MTX), cyclosporin, tacrolimus, sirolimus, leflunomide and/or mycophenolate mofetil within 4 weeks before the screening visit (all such medications should be withdrawn at least 4 weeks prior to the screening visit)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    OSE-127 High dose induction phase

    OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 3 total infusions, weeks 0, 2, and 6

    Drug: OSE-127

  • Experimental
    OSE-127 Low dose induction phase

    OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 3 total infusions, weeks 0, 2, and 6

    Drug: OSE-127

  • Placebo comparator
    Placebo induction phase

    Normal saline intravenous infusion 3 total infusions, weeks 0, 2, and 6

    Drug: Placebo

  • Experimental
    OSE-127 High dose optional extension phase

    OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 7 total infusions, weeks 10, 14, 18, 22, 26, 30, and 34

    Drug: OSE-127

Interventions

  • DrugOSE-127

    mAb antagonist to CD127 receptor (or IL-7Rα)

  • DrugPlacebo

    Normal saline

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Modified Mayo Score (MMS) at Week 10

    The Mayo Score measures disease activity for UC. The modified questionnaire has 3 domains (instead of the usual 4): 2 with questions answered by the patient (stool frequency and rectal bleeding) and 1 answered by an endoscopist (mucosal appearance at endoscopy). Each domain is graded from 0 to 3, higher values representing a worse outcome. Total score for modified Mayo Score is calculated as the sum of the three sub-scores, and ranges from 0 to 9.

    Time frame: From Baseline to Week 10

Secondary outcomes

  1. Clinical Remission Rate at Week 10

    Clinical remission rate\*: percentage of participants in clinical remission, defined as MMS ≤ 2 points and no individual sub-score of \> 1 point and a rectal bleeding at 0. \*The clinical remission rate is reported with imputation.

    Time frame: Week 10

  2. Endoscopic Remission Rate at Week 10

    Endoscopic remission rate\*: percentage of participants with an endoscopic remission, defined by an endoscopic Mayo sub-score = 0. \*The endoscopic remission rate is reported with imputation.

    Time frame: Week 10

07

Results

Posted Jun 23, 2026

Participant flow

Double-Blind Induction Period
Participant flow — Double-Blind Induction Period
MilestoneLusvertikimab 850 mg, Induction PeriodLusvertikimab 450 mg, Induction PeriodPlacebo, Induction PeriodLusvertikimab 850 mg, Open-Label Extension Period
Started5136490
Completed4732420
Not completed4470
Open-Label Extension
Participant flow — Open-Label Extension
MilestoneLusvertikimab 850 mg, Induction PeriodLusvertikimab 450 mg, Induction PeriodPlacebo, Induction PeriodLusvertikimab 850 mg, Open-Label Extension Period
Started000120
Completed000104
Not completed00016

Outcome measures

PrimaryChange From Baseline in Modified Mayo Score (MMS) at Week 10

The Mayo Score measures disease activity for UC. The modified questionnaire has 3 domains (instead of the usual 4): 2 with questions answered by the patient (stool frequency and rectal bleeding) and 1 answered by an endoscopist (mucosal appearance at endoscopy). Each domain is graded from 0 to 3, higher values representing a worse outcome. Total score for modified Mayo Score is calculated as the sum of the three sub-scores, and ranges from 0 to 9.

Time frame:
From Baseline to Week 10
Reported as:
Least squares mean · units on a scale
Change From Baseline in Modified Mayo Score (MMS) at Week 10
units on a scaleLusvertikimab 850 mgLusvertikimab 450 mgPlacebo
Change From Baseline in Modified Mayo Score (MMS) at Week 10-2.41 (-2.99 to -1.83)-2.68 (-3.44 to -1.91)-1.52 (-2.14 to -0.90)
Statistical analysis
  • Lusvertikimab 850 mg vs Placebo · ANCOVA · p = 0.036 · Least square mean difference: -0.90 · 95% CI -1.73 to -0.06
  • Lusvertikimab 450 mg vs Placebo · ANCOVA · p = 0.019 · Least square mean difference: -1.16 · 95% CI -2.12 to -0.19
SecondaryClinical Remission Rate at Week 10

Clinical remission rate\*: percentage of participants in clinical remission, defined as MMS ≤ 2 points and no individual sub-score of \> 1 point and a rectal bleeding at 0. \*The clinical remission rate is reported with imputation.

Time frame:
Week 10
Reported as:
Number · percentage of participants
Clinical Remission Rate at Week 10
percentage of participantsLusvertikimab 850 mgLusvertikimab 450 mgPlacebo
Clinical Remission Rate at Week 1012.923.84.4
Statistical analysis
  • Lusvertikimab 850 mg vs Placebo · Regression, Logistic · p = 0.161 · Odds ratio (or): 3.27 · 95% CI 0.62 to 17.12
  • Lusvertikimab 450 mg vs Placebo · Regression, Logistic · p = 0.030 · Odds ratio (or): 6.20 · 95% CI 1.19 to 32.29
SecondaryEndoscopic Remission Rate at Week 10

Endoscopic remission rate\*: percentage of participants with an endoscopic remission, defined by an endoscopic Mayo sub-score = 0. \*The endoscopic remission rate is reported with imputation.

Time frame:
Week 10
Reported as:
Number · percentage of participants
Endoscopic Remission Rate at Week 10
percentage of participantsLusvertikimab 850 mgLusvertikimab 450 mgPlacebo
Endoscopic Remission Rate at Week 1019.336.712.5
Statistical analysis
  • Lusvertikimab 850 mg vs Placebo · Regression, Logistic · p = 0.385 · Odds ratio (or): 1.69 · 95% CI 0.52 to 5.47
  • Lusvertikimab 450 mg vs Placebo · Regression, Logistic · p = 0.032 · Odds ratio (or): 3.71 · 95% CI 1.12 to 12.33

Adverse events

Collected over Double Blind Induction Period (from Week 0 to Week 10), Open-Label Extension Period (from Week 10 to Week 34). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lusvertikimab 850 mg Induction Period0/51 (0%)3/51 (5.9%)7/51 (13.7%)
Lusvertikimab 450 mg Induction Period0/36 (0%)3/36 (8.3%)9/36 (25%)
Placebo Induction Period1/49 (2%)3/49 (6.1%)12/49 (24.5%)
Lusvertikimab 850 mg Open-Label Extension Period0/120 (0%)10/120 (8.3%)49/120 (40.8%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventLusvertikimab 850 mg Induction PeriodLusvertikimab 450 mg Induction PeriodPlacebo Induction PeriodLusvertikimab 850 mg Open-Label Extension Period
Colitis UlcerativeGastrointestinal disorders0/511/361/493/120
Anal UlcerGastrointestinal disorders0/511/360/490/120
Asymptomatic Covid-19Infections and infestations0/511/360/490/120
Chest PainGeneral disorders0/510/361/490/120
Covid-19 PneumoniaInfections and infestations0/510/361/490/120
Uterine LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/510/360/490/120
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders1/510/360/490/120
Embolism VenousVascular disorders1/510/360/490/120
Covid-19Infections and infestations0/510/360/492/120
AnaemiaBlood and lymphatic system disorders0/510/360/491/120
Most frequent other events
Showing 10 of 11
Most frequent other events
EventLusvertikimab 850 mg Induction PeriodLusvertikimab 450 mg Induction PeriodPlacebo Induction PeriodLusvertikimab 850 mg Open-Label Extension Period
LymphopeniaBlood and lymphatic system disorders2/514/361/497/120
Covid-19Infections and infestations0/511/362/4912/120
Colitis UlcerativeGastrointestinal disorders2/511/363/4910/120
AnaemiaBlood and lymphatic system disorders0/511/362/497/120
PyrexiaGeneral disorders0/512/361/490/120
HypertensionVascular disorders1/510/362/490/120
Upper Respiratory Tract InfectionInfections and infestations2/510/361/490/120
NasopharyngitisInfections and infestations0/510/360/494/120
ThrombocytopeniaBlood and lymphatic system disorders0/510/360/493/120
ArthralgiaMusculoskeletal and connective tissue disorders0/510/360/493/120

Baseline characteristics

Full Analysis Set: all randomized patients with Ulcerative Colitis who received at least one dose of study treatment (2 patients excluded for Crohn's Disease).

Age, Categorical
Age, Categorical(Participants)Lusvertikimab 850 mg, Induction PeriodLusvertikimab 450 mg, Induction PeriodPlacebo, Induction PeriodTotal
<=18 years0000
Between 18 and 65 years453444123
>=65 years51511
Age, Continuous
Age, Continuous(years)Lusvertikimab 850 mg, Induction PeriodLusvertikimab 450 mg, Induction PeriodPlacebo, Induction PeriodTotal
Mean42.5 ± 15.138.8 ± 10.542.7 ± 15.941.6 ± 14.4
Sex: Female, Male
Sex: Female, Male(Participants)Lusvertikimab 850 mg, Induction PeriodLusvertikimab 450 mg, Induction PeriodPlacebo, Induction PeriodTotal
Female23132157
Male27222877
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Lusvertikimab 850 mg, Induction PeriodLusvertikimab 450 mg, Induction PeriodPlacebo, Induction PeriodTotal
Count of participants———0
Modified Mayo Score (MMS)
Modified Mayo Score (MMS)(units on a scale)Lusvertikimab 850 mg, Induction PeriodLusvertikimab 450 mg, Induction PeriodPlacebo, Induction PeriodTotal
Mean6.5 ± 1.06.0 ± 1.46.6 ± 1.26.4 ± 1.2
08

Study locations

55 sites
  • Brest Regional Hospital
    Brest, Belarus
  • Grodno University Hospital
    Grodno, Belarus
  • Gomel Regional Clinical Hospital
    Homyel, Belarus
  • City Clinical Emergency Hospital
    Minsk, Belarus
  • Vitebsk Regional Clinical Hospital
    Vitebsk, Belarus
  • UZ Leuven - Department of Gastroenterology and Hepatology
    Leuven, Belgium
  • CHU Liège
    Liège, Belgium
  • Groupe Santé CHC - Clinique du Mont Légia
    Liège, Belgium
  • Medical Center Medconsult Pleven - OOD
    Pleven, Bulgaria
  • Medical Center Medconsult Pleven
    Pleven, Bulgaria
  • Acibadem City Clinic University Multiprofile Hospital for Active Treatment - EOOD, Clinic of Gastroenterology
    Sofia, Bulgaria
  • Medical Center Asklepion - Researches in humane medicine (EOOD)
    Sofia, Bulgaria
  • Medical Center Asklepion
    Sofia, Bulgaria
  • Medical Center Hera EOOD
    Sofia, Bulgaria
  • Medical Center Hera
    Sofia, Bulgaria
  • UMHAT Tsaritsa Yoanna - ISUL - EAD
    Sofia, Bulgaria
  • Medical center VIP Clinic - OOD
    Varna, Bulgaria
  • Medical Center VIP Clinic
    Varna, Bulgaria
  • University Hospital Center Split
    Split, Croatia
  • EVEX Hospitals JSC
    Kutaisi, Georgia
  • West Regional Center of Modern Medical Technologies Ltd
    Kutaisi, Georgia
  • Institute of Clinical Cardiology
    Tbilisi, Georgia
  • Israel-Georgia Medical Research Clinic Helsicore Ltd
    Tbilisi, Georgia
  • JSC Clinic Jerarsi
    Tbilisi, Georgia
  • Multiprofile Clinic Consilium Medulla Ltd
    Tbilisi, Georgia
  • Clinexpert SMO
    Budapest, Hungary
  • II. Sz. Belgyogyaszati Klinika, Semmelweis Egyetem
    Budapest, Hungary
  • II. Sz Belgyogyasztai Intezet, Gasztroenterologia Debreceni Egyetem
    Debrecen, Hungary
  • Polana-D
    Daugavpils, Latvia
  • Liepāja Regional Hospital
    Liepāja, Latvia
  • Digestive Diseases Centre GASTRO
    Riga, Latvia
  • Pauls Stradins Clinical University Hospital
    Riga, Latvia
  • Centrum Opieki Zdrowotnej Orkan-med
    Ksawerów, Poland
  • Centrum Medyczne Med-Gastr
    Lodz, Poland
  • Oddział Kliniczny Gastroenterologii Ogólnej i Onkologicznej
    Lodz, Poland
  • Medicome Sp. z o.o.
    Oświęcim, Poland
  • Centrum Medyczne Medyk
    Rzeszów, Poland
  • WIP Warsaw IBD Point Profesor Kierkus
    Warsaw, Poland
  • Melita Medical
    Wroclaw, Poland
  • Prof. S.V. Ochapovskiy Regional Clinical Hospital No.1
    Krasnodar, Russia
  • Ryzhikh State Coloproctology Research Center
    Moscow, Russia
  • LLC Novosibirskiy Gastrocenter
    Novosibirsk, Russia
  • Medical Center Healthy Family LLC
    Novosibirsk, Russia
  • State Budgetary Healthcare Institution of the Stavropol Region - Pyatigorsk Oncology Dispensary
    Pyatigorsk, Russia
  • Saratov State Medical University
    Saratov, Russia
  • Ekaterinburg City Clinical Hospital No. 14
    Yekaterinburg, Russia
  • 301 Fairfield Medical Suite
    Cape Town, South Africa
  • Dnipropetrovsk I.I. Mechnikov Regional Clinical Hospital - Dnipropetrovsk Regional Council
    Dnipro, Ukraine
  • Prof. O.O. Salimov City Clinical Hospital #2 - Kharkiv City Council
    Kharkiv, Ukraine
  • Kryvyi Rih City Clinical Hospital #2
    Kryvyi Rih, Ukraine
  • Kyiv Regional Clinical Hospital - Kyiv Regional Council
    Kyiv, Ukraine
  • Medical Center OK!Clinic+ of International Institute of Clinical Studies LLC
    Kyiv, Ukraine
  • Ternopil University Hospital - Ternopil Regional Council
    Ternopil, Ukraine
  • Andrii Novak Transcarpathian Regional Clinical Hospital
    Uzhhorod, Ukraine
  • Municipal Institution City Clinical Hospital #6 - Therapeutic Department
    Zaporizhzhya, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Apr 2024, 42 months.

Results were first posted in Jun 2026, 2 years 1 month after primary completion.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 42 months is above that.

Counting every sponsor, half of 155 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2021
First posted
May 11, 2021
StartActual
Oct 2, 2020
Primary completionActual
Apr 30, 2024
CompletionActual
Jan 28, 2025
Results first posted
Jun 23, 2026
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04882007
Lead sponsor
OSE Immunotherapeutics
Responsible party
Sponsor
First posted
May 11, 2021
Start date
Oct 2, 2020
Primary completion
Apr 30, 2024
Completion
Jan 28, 2025
Results posted
Jun 23, 2026
Last update
Jun 23, 2026

Study contacts

Silvia Comis, MD
study director · OSE Immunotherapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion